Last reviewed · How we verify

EMS — Portfolio Competitive Intelligence Brief

EMS pipeline: 8 marketed, 0 filed, 40 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 40 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Zolpidem Hemitartrate Zolpidem Hemitartrate marketed Non-benzodiazepine hypnotic (Z-drug) GABA-A receptor (alpha-1 subunit selective) Neurology / Sleep Medicine
Pantogar Pantogar marketed Other
Vitamin B Complex + Vitamin C Vitamin B Complex + Vitamin C marketed Vitamin supplement / Nutritional supplement Nutritional supplementation / General wellness
Afrin Afrin marketed Other
Prograf Prograf marketed Other
Neosil complete Neosil complete marketed
DEC103 DEC103 marketed Other
Neosil Neosil marketed Other
BALI association BALI association phase 3
PIEMONTE PIEMONTE phase 3
Tanzânia association Tanzânia association phase 3
LID104 LID104 phase 3 SSRI 5-HT receptor Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Merck Sharp & Dohme LLC · 5 shared drug classes
  2. GlaxoSmithKline · 4 shared drug classes
  3. AstraZeneca · 4 shared drug classes
  4. Ahn-Gook Pharmaceuticals Co.,Ltd · 4 shared drug classes
  5. Sanofi · 4 shared drug classes
  6. Allergan · 3 shared drug classes
  7. Hanlim Pharm. Co., Ltd. · 3 shared drug classes
  8. Astellas Pharma Inc · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for EMS:

Cite this brief

Drug Landscape (2026). EMS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ems. Accessed 2026-05-14.

Related